View Older Stories View More Recent Stories

Jun 15, 2020 08:00AM AbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society
Jun 13, 2020 02:30AM VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients
Jun 12, 2020 04:45PM AbbVie Recommends Shareholders Reject TRC Capital's "Mini-Tender" Offer
Jun 12, 2020 03:04PM AbbVie (ABBV) Presents New Late-Breaking Data Showing SKYRIZI Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX at 52 Weeks
Jun 12, 2020 03:02PM AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
Jun 10, 2020 08:20AM AbbVie (ABBV) Reports Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with RA
Jun 10, 2020 08:15AM Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis
Jun 10, 2020 06:04AM Genmab (GMAB) and AbbVie (ABBV) Announce Broad Oncology Collaboration, Genmab to Receive Upfront Payment of $750M With Total Potential Milestones of Up to $3.15B
Jun 10, 2020 06:00AM Genmab and AbbVie Announce Broad Oncology Collaboration
Jun 10, 2020 06:00AM AbbVie and Genmab Announce Broad Oncology Collaboration
Jun 6, 2020 08:30AM AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
Jun 5, 2020 06:04AM AbbVie (ABBV) Enters Collaboration with Harbour BioMed, Utrecht University and Erasmus Medical Center to Develop Monoclonal Antibody Therapy to Prevent & Treat COVID-19
Jun 5, 2020 06:00AM AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
Jun 5, 2020 06:00AM AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
Jun 4, 2020 08:32AM AbbVie (ABBV) Announces New Long-term Data from RINVOQ Phase 3 Studies in Rheumatoid Arthritis Presented at EULAR
Jun 4, 2020 08:30AM New Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
Jun 3, 2020 08:00AM AbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference
Jun 1, 2020 11:41AM AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for RINVOQ for Treatment of Adults with Active Psoriatic Arthritis
Jun 1, 2020 11:40AM AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Jun 1, 2020 08:30AM Allergan Aesthetics Launches Dedicated Multi-Channel Campaign To Contact Patients Who May Not Be Aware Of The BIOCELL® Recall And To Improve Tracking Information For U.S. Breast Implant Patients
Jun 1, 2020 01:00AM AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
May 29, 2020 04:15PM AbbVie (ABBV), Neurocrine (NBIX) Announce FDA Approves First Oral Medication for Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
May 29, 2020 04:14PM FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
May 27, 2020 08:30AM AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
May 27, 2020 08:08AM Ironwood Pharma (IRWD), AbbVie (ABBV) Report Top-Line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with IBS-D
May 15, 2020 08:30AM AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio
May 14, 2020 08:00AM AbbVie to Present at the UBS Virtual Healthcare Conference
May 8, 2020 04:17PM AbbVie (ABBV) Completes Acquisition of Allergan (AGN)
May 8, 2020 04:15PM AbbVie Completes Transformative Acquisition of Allergan
May 5, 2020 05:54PM AbbVie (ABBV), Allergan (AGN) Merger Cleared by FTC
May 5, 2020 05:51PM AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan
May 1, 2020 07:43AM AbbVie Reports First-Quarter 2020 Financial Results
Apr 21, 2020 03:23PM AbbVie (ABBV) Announces IMBRUVICA Received 11th FDA Approval
Apr 21, 2020 03:22PM IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
Apr 2, 2020 08:00AM AbbVie to Host First-Quarter 2020 Earnings Conference Call
Mar 31, 2020 07:24PM AbbVie Donates $35 Million for COVID-19 Relief to Support Healthcare Systems, Patients and Communities
Mar 23, 2020 08:03AM AbbVie (ABBV) Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA in Combination with Azacitidine in Patients with AML
Mar 23, 2020 08:00AM AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Mar 17, 2020 04:31PM AbbVie (ABBV), Allergan (AGN) Sign Consent Decree Agreement with FTC Staff on Pending Transaction
Mar 17, 2020 04:30PM AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
Mar 12, 2020 07:01AM AbbVie (ABBV) Receives EC Approval of VENCLYXTO Combination Regimen for Patients with Previously-Untreated CLL
Mar 12, 2020 07:00AM AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Mar 9, 2020 08:45AM AbbVie (ABBV) Says It's Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19
Mar 9, 2020 08:45AM AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19
Mar 6, 2020 07:01AM AbbVie (ABBV) Announces EC Grants Marketing Authorization Shortening MAVIRET Treatment Duration to Eight Weeks for Some HCV Patients
Mar 6, 2020 07:00AM European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 an
Mar 3, 2020 08:01AM AbbVie (ABBV), Allergan Receive Final European Approval to Close Pending Transaction
Mar 3, 2020 08:00AM AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
Mar 2, 2020 05:54AM AbbVie (ABBV) Reports Update from Ph. 3 Study Evaluating VENCLEXTA (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with AML
Feb 28, 2020 06:53PM AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)
View More Recent Stories View Older Stories